<div id="readability-page-1"><p>Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV - Get Free Report) have been given an average recommendation of &#34;Moderate Buy&#34; by the seven brokerages that are presently  covering the company, Marketbeat.com reports. One research analyst  has rated the stock with a sell rating, one  has issued  a hold rating, four have given a buy rating and one  has given a strong buy rating to  the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $7.25.</p><div><p><span></span><span>Get <strong>Plus Therapeutics</strong> alerts:</span></p></div><p>PSTV has been the subject of a number of recent analyst reports. Ascendiant Capital Markets lowered their price target on Plus Therapeutics from $21.00 to $19.00 and set a &#34;buy&#34; rating for the company in a research note on Friday, November 21st. D Boral Capital upgraded shares of Plus Therapeutics from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Wednesday, September 3rd. Zacks Research lowered shares of Plus Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, November 11th. D. Boral Capital  reissued a &#34;buy&#34; rating and issued a $5.00 price target on shares of Plus Therapeutics in a report on Thursday, December 11th. Finally, HC Wainwright  restated a &#34;buy&#34; rating and issued a $2.00 price objective on shares of Plus Therapeutics in a research report on Wednesday, November 26th.</p><p><b>Get Our Latest Research Report on Plus Therapeutics</b></p><h2>Plus Therapeutics Stock Performance</h2><p>PSTV opened at $0.57 on Friday. The company has a fifty day moving average price of $0.59 and a two-hundred day moving average price of $0.51. The firm has a market capitalization of $78.13 million, a PE ratio of -0.30 and a beta of 0.82. Plus Therapeutics has a 52 week low of $0.16 and a 52 week high of $2.31. </p><p>Plus Therapeutics (NASDAQ:PSTV - Get Free Report) last posted its quarterly earnings results on Thursday, October 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The firm had revenue of $1.40 million during the quarter, compared to analyst estimates of $1.50 million.  Equities analysts forecast that  Plus Therapeutics will post -2.3 EPS for the current year. </p><h2>Hedge Funds Weigh In On Plus Therapeutics</h2><p>Institutional investors have recently modified their holdings of the business. Jane Street Group LLC bought a new stake in  Plus Therapeutics during the 2nd quarter worth approximately $41,000.  Susquehanna International Group LLP acquired a new position in shares of  Plus Therapeutics in the third quarter valued at approximately $46,000.  Scientech Research LLC bought a new stake in shares of  Plus Therapeutics during the third quarter worth $100,000.  Finally, Altium Capital Management LLC bought a new stake in shares of  Plus Therapeutics during the third quarter worth $628,000. Institutional investors own  3.28% of the company's stock. </p><h2>About Plus Therapeutics</h2> (Get Free Report)<p>Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company's lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.  </p><p>The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.</p><h2>Read More</h2><ul><li>Five stocks we like better than Plus Therapeutics</li><li>How is Compound Interest Calculated?</li><li>These 3 Banks Are Rallying Into Year-End, But Will It Continue?</li><li>Stock Sentiment Analysis: How it Works</li><li>3 Surging Stocks Just Got the Ultimate Stamp of Approval From the S&amp;P 500</li><li>Why Are These Companies Considered Blue Chips?</li><li>This ETF Caught a Major Tailwind After the Fed’s Rate Cut</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFNUVg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFNUVg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Plus Therapeutics Right Now?</h2><p>Before you consider Plus Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Plus Therapeutics wasn't on the list.</p><p>While Plus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PSTV

<p>Plus Therapeutics, Inc. (NASDAQ:PSTV) has received an average "Moderate Buy" rating from seven brokerages. The stock has one sell, one hold, four buy, and one strong buy ratings. The average 1-year price target is $7.25. Recent analyst actions include Ascendiant Capital Markets lowering its price target to $19.00 and D Boral Capital upgrading to a "strong-buy." The company specializes in targeted radiotherapeutics for oncology, with its lead candidate in Phase 2 development.</p>

Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Average Rating of "Moderate Buy" from Analysts